We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other biotech stocks.
No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies.
The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This “older, richer & sicker” population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you’ll see many more biotech stocks starting to pop to the upside over the coming years.
Methodology
For this article, I screened the top-performing biotech stocks year-to-date.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A biochemist in a laboratory conducting research on a new psychiatric therapy.
GH Research PLC (NASDAQ:GHRS)
Number of Hedge Fund Holders In Q4 2024: 10
GH Research PLC (NASDAQ:GHRS) is a biopharma company working on psychiatric and neurological disorders by developing novel and proprietary mebufotenin (5-MeO-DMT) therapies for conditions like treatment-resistant depression.
The stock is up significantly so far in 2025 after the announcement of positive Phase 2b clinical trial results for their lead product candidate GH001 in treatment-resistant depression (TRD).
It showed a significant placebo-adjusted MADRS reduction of -15.5 on Day 8 and an impressive 57.5% remission rate compared to 0% in the placebo group. 78% of participants sustained remission.
The consensus price target of $30.6 implies 187.32% upside.
GH Research PLC (NASDAQ:GHRS) is up 52.14% year-to-date.
Overall GHRS ranks 11th on our list of the biotech stocks that are skyrocketing so far in 2025. While we acknowledge the potential of GHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GHRS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Why These 15 E-Commerce Stocks Are Skyrocketing So Far In 2025 and Why These 15 Insurance Stocks Are Skyrocketing So Far In 2025
Disclosure: None. This article is originally published at Insider Monkey.
